Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ceritinib dihydrochloride (LDK378 dihydrochloride) 是一种选择性的、口服具有活性的、ATP 竞争性的ALK 酪氨酸激酶抑制剂 (IC50:200 pM)。它还抑制IGF-1R (IC50:8 nM),InsR (IC50:7 nM) 和 STK22D (IC50:23 nM)。它显示出良好的抗肿瘤作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 196 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 638 | 现货 | ||
25 mg | ¥ 1,130 | 现货 | ||
50 mg | ¥ 1,890 | 现货 | ||
100 mg | ¥ 2,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 748 | 现货 |
产品描述 | Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, InsR, and STK22D (IC50 values of 8, 7, and 23 nM, respectively), shows great antitumor potency |
靶点活性 | ALK:0.2 nM , INSR:7 nM , STK22D:23 nM, IGF-1R:8 nM |
体外活性 | In vitro experiments also showed that lipopolysaccharide (LPS)-induced migration of MDSCs was similarly owing to the activation of GRK2 and upregulation of CCR2 by LPS, whereas the treatment with LDK378 partially blocked the LPS-induced phosphorylation of p38 and GRK2 and decreased the expression of CCR2 on the cell surface, therefore leading to the suppression of MDSC migration[1]. |
体内活性 | LDK378 significantly improved the survival of CLP-induced polymicrobial septic mice, which was paralleled by reduced organ injury, decreased release of inflammatory cytokines and decreased recruitment of MDSCs to the spleen.?Importantly, LDK378 inhibited the migration of MDSCs to the spleen by blocking the CLP-mediated upregulation of CC chemokine receptor 2 (CCR2), a chemokine receptor critical for the recruitment of MDSCs.?Mechanistically, LDK378 treatment blocked the CLP-induced CCR2 upregulation of MDSCs via partially inhibiting the phosphorylation of p38 and G-protein-coupled receptor kinase-2 (GRK2) in bone marrow MDSCs of septic mice[1]. |
别名 | LDK378 dihydrochloride, 双盐酸盐色瑞替尼 |
分子量 | 631.06 |
分子式 | C28H38Cl3N5O3S |
CAS No. | 1380575-43-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 5 mg/mL (7.92 mM), Sonification is recommended.
DMSO: 95 mg/mL (150.54 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 1.5846 mL | 7.9232 mL | 15.8464 mL | 39.6159 mL |
5 mM | 0.3169 mL | 1.5846 mL | 3.1693 mL | 7.9232 mL | |
DMSO | 10 mM | 0.1585 mL | 0.7923 mL | 1.5846 mL | 3.9616 mL |
20 mM | 0.0792 mL | 0.3962 mL | 0.7923 mL | 1.9808 mL | |
50 mM | 0.0317 mL | 0.1585 mL | 0.3169 mL | 0.7923 mL | |
100 mM | 0.0158 mL | 0.0792 mL | 0.1585 mL | 0.3962 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ceritinib dihydrochloride 1380575-43-8 Angiogenesis Tyrosine Kinase/Adaptors IGF-1R ALK inhibit Inhibitor ALK tyrosine kinase receptor LDK378 LDK 378 Anaplastic lymphoma kinase (ALK) LDK378 Dihydrochloride Cluster of differentiation 246 Insulin Receptor LDK-378 LDK378 dihydrochloride Ceritinib Dihydrochloride Ceritinib Anaplastic lymphoma kinase CD246 LDK-378 Dihydrochloride LDK 378 Dihydrochloride 双盐酸盐色瑞替尼 inhibitor